GlassScriptPhysician profile
Elliotte D Moss
NPI 1548245632
$3,988.63
in general payments reported to CMS, 2019-2025
28 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $74.18 · 2021: $417 · 2022: $635 · 2023: $1,133 · 2024: $592 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $767.98 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $395.29 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $382.60 | 2021-2025 | |
| Pfizer INC. | $333.90 | 2019-2023 | |
| Lilly USA, LLC | $325.61 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $279.50 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $278.33 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $158.67 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.27 | 2019-2025 | Ofev, Jardiance |
| Dexcom, INC. | $128.06 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $117.62 | 2021-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $106.00 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $75.90 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $71.71 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.26 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $57.95 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $51.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pulmonx Corporation | $43.13 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $39.30 | 2024 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $33.85 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $32.55 | 2023-2024 | Onpattro, Givlaari |
| Eisai INC. | $20.08 | 2025 | |
| Adlon Therapeutics L.P. | $17.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.66 | 2022 | |
| Seqirus USA INC | $14.52 | 2022 | |
| Inari Medical, INC. | $14.06 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $13.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliotte Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.